Loss of virus-specific T-cell responses in HCV exposed uninfected injection drug users with drug rehabilitation

Journal of Infectious Diseases

Volumn 203, Issue 6, 2011, Pages 847-853

  Thurairajah, Prem H ^a   Hegazy, Doha ^a   Demaine, Andrew ^a   Kaminski, Edward R ^a,b   Cramp, Matthew E ^a,b  

^a PLYMOUTH UNIVERSITY PENINSULA SCHOOLS OF MEDICINE AND DENTISTRY   (United Kingdom)

^b DERRIFORD HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; HEPATITIS C ANTIBODY;

ADULT; ARTICLE; CELL ISOLATION; CELL SPECIFICITY; CELLULAR IMMUNITY; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG DEPENDENCE; DRUG DEPENDENCE TREATMENT; ENZYME LINKED IMMUNOSPOT ASSAY; EXPOSURE; FEMALE; FOLLOW UP; HEPATITIS C VIRUS; HUMAN; HUMAN CELL; MALE; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PRISONER; QUESTIONNAIRE;

ADULT; COHORT STUDIES; ENZYME-LINKED IMMUNOSPOT ASSAY; FEMALE; GREAT BRITAIN; HEPACIVIRUS; HEPATITIS C ANTIBODIES; HEPATITIS C ANTIGENS; HUMANS; INTERFERON-GAMMA; MALE; MIDDLE AGED; NEEDLE SHARING; PRISONERS; QUESTIONNAIRES; RISK FACTORS; SUBSTANCE ABUSE, INTRAVENOUS; T-LYMPHOCYTES; YOUNG ADULT;

EID: 79952357692     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/jiq121     Document Type: Article

References (20)

1. Tseng FC, O'Brien TR, Zhang M, et al. Seroprevalence of hepatitis C virus and hepatitis B virus among San Francisco injection drug users, 1998 to 2000. Hepatology 2007; 46:666-71.
2. Hegazy D, Thurairajah P, Metzner M, et al. Interleukin 12B gene polymorphism and apparent resistance to hepatitis C virus infection. Clin Exp Immunol 2008; 152:538-41. (Pubitemid 351661506)
3. Zeremski M, Shu MA, Brown Q, et al. Hepatitis C virus-specific T-cell immune responses in seronegative injection drug users. J Viral Hepat 2009; 16:10-20.
4. Thurairajah PH, Hegazy D, Chokshi S, et al. Hepatitis C virus (HCV)-specific T cell responses in injection drug users with apparent resistance to HCV infection. J Infect Dis 2008; 198:1749-55.
5. Freeman AJ, French RA, Post JJ, et al. Prevalence of production of virus-specific interferon-gamma among seronegative hepatitis C-resistant subjects reporting injection drug use. J Infect Dis 2004; 190:1093-7.
6. Koziel MJ, Wong DK, Dudley D, et al. Hepatitis C virus-specific cytolytic T lymphocyte and T helper cell responses in seronegative persons. J Infect Dis 1997; 176:859-66. (Pubitemid 27411026)
7. Meyer MF, Lehmann M, Cornberg M, et al. Clearance of low levels of HCV viremia in the absence of a strong adaptive immune response. Virol J 2007; 4:58.
8. Mizukoshi E, Eisenbach C, Edlin BR, et al. Hepatitis C virus (HCV)-specific immune responses of long-term injection drug users frequently exposed to HCV. J Infect Dis 2008; 198:203-12. (Pubitemid 352019285)
9. Post JJ, Pan Y, Freeman AJ, et al. Clearance of hepatitis C viremia associated with cellular immunity in the absence of seroconversion in the hepatitis C incidence and transmission in prisons study cohort. J Infect Dis 2004; 189:1846-55. (Pubitemid 38657221)
10. Allwright S, Bradley F, Long J, et al. Prevalence of antibodies to hepatitis B, hepatitis C, and HIV and risk factors in Irish prisoners: results of a national cross sectional survey. BMJ 2000; 321:78-82. (Pubitemid 30438479)
11. Hellard ME, Hocking JS, Crofts N. The prevalence and the risk behaviours associated with the transmission of hepatitis C virus in Australian correctional facilities. Epidemiol Infect 2004; 132:409-15. (Pubitemid 38714116)
12. Malliori M, Sypsa V, Psichogiou M, et al. A survey of bloodborne viruses and associated risk behaviours in Greek prisons. Addiction 1998; 93:243-51. (Pubitemid 28067798)
13. Stark K, Bienzle U, Vonk R, et al. History of syringe sharing in prison and risk of hepatitis B virus, hepatitis C virus, and human immunodeficiency virus infection among injecting drug users in Berlin. Int J Epidemiol 1997; 26:1359-66. (Pubitemid 28010456)
14. Weild AR, Gill ON, Bennett D, et al. Prevalence of HIV, hepatitis B, and hepatitis C antibodies in prisoners in England and Wales: a national survey. Commun Dis Public Health 2000; 3:121-6.
15. Bird AG, Gore SM, Hutchinson SJ, et al. Harm reduction measures and injecting inside prison versus mandatory drugs testing: results of a cross sectional anonymous questionnaire survey. The European Commission Network on HIV Infection and Hepatitis in Prison. BMJ 1997; 315:21-4. (Pubitemid 27271678)
16. Backmund M, Meyer K, Wachtler M, et al. Hepatitis C virus infection in injection drug users in Bavaria: risk factors for seropositivity. Eur J Epidemiol 2003; 18:563-8. (Pubitemid 36899562)
17. Garfein RS, Doherty MC, Monterroso ER, et al. Prevalence and incidence of hepatitis C virus infection among young adult injection drug users. J Acquir Immune Defic Syndr Hum Retrovirol 1998; 1:S19.
18. Roy KM, Hutchinson SJ, Wadd S, et al. Hepatitis C virus infection among injecting drug users in Scotland: a review of prevalence and incidence data and the methods used to generate them. Epidemiol Infect 2007; 135:433-42. (Pubitemid 46443429)
19. Kaul R, Dong T, Plummer FA, et al. CD8(+) lymphocytes respond to different HIV epitopes in seronegative and infected subjects. J Clin Invest 2001; 107:1303-10. (Pubitemid 32494547)
20. Kaul R, Rutherford J, Rowland-Jones SL, et al. HIV-1 Env-specific cytotoxic T-lymphocyte responses in exposed, uninfected Kenyan sex workers: a prospective analysis. AIDS 2004; 18:2087-9. (Pubitemid 39463364)